Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Real-world analysis of bortezomib-dex-rituximab in patients with Waldenström macroglobulinaemia finds ORR 88%, CR 6%, VGPR 24%, median EFS 33 months, no impact of MYD88 L265P mutation or double mutation MYD88/CXCR4 on OS or EFS.”

“Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World Analysis”

Authors: Thomas Hueso, Grégory Lazarian, Paul Chauvet, Adrien Chauchet, Ramy Rahmé, Sabine Brechignac, Vincent Lévy, Salomon Manier, Damien Roos-Weil, David Ghez, Claude Gardin, Fanny Baran-Marszak, Eric Durot, Pierre Morel, Thorsten Braun.

Myeloma Paper of the Day, March 22nd, suggested by Robert Orlowski

More posts featuring Robert Orlowski.